By Mary de Wet

 

Elanco Animal Health Inc. received conditional approval from the Food and Drug Administration on Monday for its drug Varenzin-CA1 to treat anemia in cats with chronic kidney disease.

The agency said Varenzin-CA1 helps to increase production of erythropoietin in the kidney, which in turn stimulates the bone marrow to produce more red blood cells.

The current treatments available for nonregenerative anemia in cats with CKD include blood transfusion, supplemental iron therapy and erythropoietin replacement, the FDA said.

Under conditional approval, the FDA has concluded that the drug is safe for its intended purpose and has a reasonable expectation of being effective. Cats suffering from the disease can receive the treatment while full effectiveness data is being collected, the agency said.

The initial conditional approval is valid for one year with the potential for four annual renewals, the FDA said.

 

Write to Mary de Wet at mary.dewet@dowjones.com

(END) Dow Jones Newswires

May 01, 2023 15:32 ET (19:32 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Elanco Animal Health Charts.
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Elanco Animal Health Charts.